Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
about
Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?Hepatitis C virus infection in the human immunodeficiency virus infected patient.Periportal CD4+ cell infiltration increases in HIV/hepatitis C virus-coinfected patients commencing ART, whereas CD8+ cells clear from the liver.Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug usersHuman immunodeficiency virus and liver disease: An update.Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy.Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment.Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
P2860
Q26798469-F4BB814C-23F8-4D95-9246-B2B4485B18E4Q34168504-D943A571-5A75-47A3-A26A-7731F8E682D0Q35105508-EDF76ABC-7426-4AF6-AC95-7EAF4F94378BQ35111937-B6690D85-AE44-41E0-86D4-A5F8571EC195Q35628281-7CBAAA21-3FE2-4177-9477-51997E9BE5F6Q36378109-D2703AF4-9603-4964-A47F-52149495AFC9Q36708245-FFCE7A84-14B1-41FD-9ADA-0AF852105B2CQ40041670-120A305B-B671-45B6-9400-8C48D14CCEADQ40296161-02342080-B066-45EF-8272-EE764D341353Q40399713-C907A0D6-8945-433C-8B3E-8DEBC8488A94Q40750320-C03A001A-E600-49FD-9576-4584F06F72F2Q41733883-9437025B-437B-4A5A-A8CF-3B422E97B6EAQ47551818-BD92C424-5CFF-422B-AF00-80F6C142B955
P2860
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@en
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@nl
type
label
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@en
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@nl
prefLabel
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@en
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@nl
P2093
P50
P356
P1433
P1476
Antiretroviral therapy and sus ...... the ANRS CO 13 HEPAVIH cohort.
@en
P2093
ANRS CO 13 HEPAVIH Study Group
Anne Gervais
Daniel Garipuy
Daniel Vittecoq
Dominique Salmon
Firouze Bani-Sadr
Hélène Fontaine
Marc-Antoine Valantin
Marc-Arthur Loko
Maria Winnock
P304
P356
10.3851/IMP2419
P577
2012-10-10T00:00:00Z